Mass azithromycin distribution and antibiotic resistance in the gut and nasopharynx: a cluster-randomized trialOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This trial measured how mass azithromycin distribution to young children affects antibiotic resistance in the gut and nasopharynx. It was the antimicrobial resistance arm of the AVENIR trial in Niger. The co-primary outcome was the load of macrolide resistance determinants in pooled community-level rectal and nasopharyngeal samples. Samples were collected 6 months after four semiannual treatments. Metagenomic DNA sequencing quantified resistance genes and microbiome composition. Comparisons followed a hierarchical, family-wise error controlled testing order across three arms.
Who was studied?
The study enrolled communities in the Dosso region of Niger, where seasonal malaria chemoprevention was already routine. From 3,000 randomized villages, 150 were selected for resistance monitoring, 50 per arm. Children aged 1 to 59 months received semiannual azithromycin or placebo, dosed by weight or height. Roughly 30 children per village were sampled. In total, 4,382 rectal and 4,402 nasopharyngeal swabs were pooled, sequenced, and analyzed. Study drug coverage exceeded 93% across arms over four distributions.
What were the most important findings?
In the gut, macrolide resistance determinants were 1.16-fold higher in the child-azithromycin arm than placebo, with a 95% confidence interval of 1.06 to 1.28 and p below 0.01. Infant-only treatment showed no detectable gut difference versus placebo. An erythromycin ribosome methylation gene drove this change, rising 7.11-fold in child-azithromycin versus placebo. In the nasopharynx, macrolide resistance did not differ significantly between arms. No co-selection appeared for 20 non-macrolide antibiotic classes, including betalactams, and overall microbiome diversity was unchanged.
What are the greatest implications of this study?
The findings confirm that repeated azithromycin distribution selects for gut macrolide resistance, though the 16% increase was more modest than in earlier Niger studies. High background resistance and possible spillover between communities may have blunted the measured effect. Reassuringly, no resistance to other antibiotic classes was detected during the 6-month surveillance window. The authors caution these results are limited to this setting and timeframe. They argue mortality benefits must be weighed against resistance risks, and that phenotypic testing and long-term surveillance remain essential as programs expand.